{"id":"NCT01910636","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection","officialTitle":"A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 2 HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2014-03","completion":"2014-06","firstPosted":"2013-07-29","resultsPosted":"2015-03-24","lastUpdate":"2015-03-24"},"enrollment":153,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Sofosbuvir","otherNames":["GS-7977","PSI-7977","Sovaldi®"]},{"type":"DRUG","name":"RBV","otherNames":["Copegus®"]}],"arms":[{"label":"Sofosbuvir+RBV 12 weeks","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus ribavirin (RBV) in Japanese participants with chronic genotype 2 hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF+RBV Treatment Naive","deltaMin":97.8,"sd":null},{"arm":"SOF+RBV Treatment Experienced","deltaMin":95.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":153},"commonTop":["Nasopharyngitis","Anaemia","Headache","Malaise","Pruritus"]}}